Oppenheimer Initiates Coverage On SAB Biotherapeutics with Outperform Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on SAB Biotherapeutics with an Outperform rating and set a price target of $12.
August 28, 2024 | 9:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on SAB Biotherapeutics with an Outperform rating and a price target of $12, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a $12 price target by Oppenheimer suggests a positive outlook for SAB Biotherapeutics. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100